Medtide Inc., CPC Scientific’s Parent Company, Debuts on Hong Kong Stock Exchange

MEDTIDE INC. is a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in peptides. The Company provides end-to-end services from early discovery and preclinical research to clinical development and commercial manufacturing. Headquartered in Hangzhou, China, the Company operates commercial manufacturing sites and offices in both China and the United States.

With over 20 years of experience in the peptide field, MEDTIDE INC. is a globally integrated CRDMO with comprehensive service capabilities. Our CRDMO services cover the full pharmaceutical development lifecycle, including:

1. CRO services – Discovery and synthesis of novel peptide chemical entities (NCEs);
2. CDMO services – Peptide Chemistry, Manufacturing, and Controls (CMC) development and commercial production.

To date, we have served over 1,000 clients across more than 50 countries, including major markets such as China, the United States, Japan, Europe, South Korea, and Australia, providing peptide drug synthesis, development, production, and regulatory CMC support in compliance with global standards.

As a trusted and steadily growing partner, MEDTIDE INC. has established long-term collaborations with many clients. Through close partnerships, we help bring life-changing therapies to market—always placing patients at the center and advancing global human health.